 Shares of Puma Biotechnology NASDAQ:PBYI rose 0.32 in after-market trading after the company reported Q2 results.Quarterly Results Earnings per share increased 136.08 year over year to 0.35, which beat the estimate of 0.30.Revenue of 70,600,000 higher by 30.98 from the same period last year, which beat the estimate of 58,210,000.Guidance Earnings guidance hasnt been issued by the company for now.Puma Biotechnology hasnt issued any revenue guidance for the time being.Conference Call Details Date: Aug 06, 2020View more earnings on PBYITime: 04:30 PMET Webcast URL: 52-week high: 15.00Companys 52-week low was at 5.50Price action over last quarter: down 9.91Company Overview Puma Biotechnology is a biotechnology company focused on developing novel therapeutics for the treatment of cancer. Puma licenses the commercial rights to its current drug candidates. The company expects to augment its product pipeline by acquiring, through license or otherwise, additional drug candidates for research and development and potential commercialization. In evaluating potential drug candidates, Puma employs disciplined decision criteria favoring drug candidates that have undergone at least some clinical study.See more from Benzinga Recap: Alteryx Q2 Earnings Switch: Q2 Earnings Insights GW Pharmaceuticals: Q3 Earnings InsightsC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 